Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.49 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8102792 | 0.85 | CYP1A2 (0.73) | CYP1A2CYP2C9CYP2C19L3MBTL1LMNA | |
| SCHEMBL9447193 | 0.83 | CYP1A2 (0.56) | GRM4CYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL9833799 | 0.82 | GRM4 (0.61) | GRM4HDAC6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9730182 | 0.82 | GRM4 (0.61) | GRM4HDAC6LMNAMAPTMEN1 | |
| SCHEMBL9430579 | 0.82 | CYP1A2 (0.52) | CYP1A2CYP2C9CYP2C19L3MBTL1LMNA | |
| SCHEMBL334142 | 0.82 | L3MBTL1 (0.64) | L3MBTL1LMNAMAPTMEN1KMT2A | |
| SCHEMBL7426198 | 0.81 | CYP1A2 (0.55) | CYP1A2CYP2C9CYP2C19L3MBTL1LMNA | |
| SCHEMBL1285002 | 0.81 | CYP1A2 (0.59) | GRM4CYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL30223469 | 0.81 | CYP1A2 (0.59) | GRM4CYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL27413036 | 0.81 | GRM4 (0.59) | GRM4HDAC6CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120058658-A | Preparation method of 7-chloro-2-ethyl-2, 3-dihydrobenzofuran-4-ol | 无锡捷化医药科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-10364240-B2 | Aryl sulfonamides | ChemoCentryx. Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-9890148-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170369483-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| EP-2060566-B1 | Poly-substituted aryls | DOW AGROSCIENCES LLC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| EP-1798223-B2 | Aryl sulfonamides | CHEMOCENTRYX INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| CN-102731382-A | 6-(poly-substituted aryl)-4-aminopicolinates and their use as herbicides | DOW AGROSCIENCES LLC | 2012-10-17 | — | — | CN | disclosed |
| CN-102731381-A | 6-(poly-substituted aryl)-4-aminopicolinates and their use as herbicides | DOW AGROSCIENCES LLC | 2012-10-17 | — | — | CN | disclosed |
| WO-2007082098-A2 | 6-(POLY-SUBSTITUTED ARYL)-4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2007-07-19 | — | — | WO | disclosed |
| EP-1798223-A2 | Aryl sulfonamides | ChemoCentryx Inc (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20060111351-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2005112925-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2005-12-01 | — | — | WO | disclosed |
| US-6939885-B2 | Aryl sulfonamides | CHEMOCENTRYX (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1562940-A2 | ARYL SULFONAMIDES | ChemoCentryx Inc (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050165067-A1 | Aryl sulfonamides | CHEMOCENTRYX | 2005-07-28 | — | — | US | disclosed |
| US-20050137193-A1 | Aryl sulfonamides | CHEMOCENTREYX | 2005-06-23 | — | — | US | disclosed |
| US-20040171654-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2004-09-02 | — | — | US | disclosed |
| WO-2004046092-A2 | ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137193-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | GRM4 897/4885HDAC6 503/4885CYP1A2 1855/4885 |
| US-10364240-B2 | Aryl sulfonamides | CCR9, CCR1, CCR2 | GRM4 897/4885HDAC6 503/4885CYP1A2 1855/4885 |
| US-20060111351-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | GRM4 897/4885HDAC6 503/4885CYP1A2 1855/4885 |
| US-20170369483-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | GRM4 897/4885HDAC6 503/4885CYP1A2 1855/4885 |
| US-20150080351-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | GRM4 897/4885HDAC6 503/4885CYP1A2 1855/4885 |
| US-20040171654-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | GRM4 897/4885HDAC6 503/4885CYP1A2 1855/4885 |
| US-20050165067-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | GRM4 897/4885HDAC6 503/4885CYP1A2 1855/4885 |
| US-20130267492-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | GRM4 897/4885HDAC6 503/4885CYP1A2 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.